diabetes
Sanofi’s Toujeo approved in Japan
July 3, 2015Manufacturing and Production, Sales and Marketing Japan, Lantus Lantus XR, Sanofi, diabetes, toujeo, type diabetes
The Ministry of Health, Labor and Welfare in Japan has given Sanofi a marketing authorisation for the diabetes drug the …
Boehringer and Vitae Pharma drug fails in mid-stage trial
July 1, 2015Research and Development BI, Boehringer, Boehringer Ingelheim, Vitae Pharmaceuticals, diabetes, type 2 diabetes
A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a …
Merck diabetes drug gets CV trial boost
June 9, 2015Research and Development, Sales and Marketing Januvia, Merck, cv, diabetes, sitagliptin
Merck’s diabetes drug Januvia has been given a boost following worries over side effects for patients after a trial revealed …
Novo Nordisk launches diabetes combination
June 8, 2015Sales and Marketing Novo Nordisk, Xutolphy, ada, diabetes
Diabetes specialist firm Novo Nordisk has launched a new treatment in the UK which combines two of the Danish firm’s …
AstraZeneca makes a move into precision medicine
May 13, 2015Research and Development, Sales and Marketing AstraZeneca, Precision Medicine, cardiovascular diseases, diabetes, mhi
AstraZeneca has signalled its intention to ramp up the use of personalised medicine strategies to find new candidate drugs and …
Novo Nordisk invests in haemophilia with Denmark facility
May 5, 2015Manufacturing and Production, Sales and Marketing Novo Nordisk, diabetes, haemophilia, novoseven
Novo Nordisk is spending around $225 million on a new facility in Kalundborg, Denmark to produce active pharmaceutical ingredients for haemophilia …
AZ and Takeda diabetes drugs get FDA safety update
April 15, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, diabetes, saxagliptin
An FDA advisory committee has said that the labels of two type 2 diabetes drugs should be changed to warn …
AstraZeneca partners with PatientsLikeMe
April 14, 2015Sales and Marketing AstraZeneca, Lupus, PatientsLikeMe, Roche, diabetes, oncology, respiratory disease
AstraZeneca has signed a five-year agreement with PatientsLikeMe to give the pharma firm access to the latter’s global network of …
Novo Nordisk opens insulin plant in Russia
April 10, 2015Manufacturing and Production, Sales and Marketing Novo Nordisk, Russia, diabetes, flexpen, insulin, kaluga, penfill
Denmark’s Novo Nordisk has opened a new manufacturing facility in Russia to produce more of its diabetes offerings in the …
FDA to look again at Novo Nordisk insulin submissions
April 8, 2015Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, Tresiba, diabetes, insulin degludec
Diabetes specialist firm Novo Nordisk has resubmitted its applications for two insulins to the FDA, along with new interim safety …
Takeda offers $2.2 billion to resolve Actos damages claims
April 1, 2015Sales and Marketing Actos, Cancer, Takeda, bladder, diabetes, heart, pioglitazone
Takeda has attempted to settle its hefty damages bill over claims it was hiding cancer risks in its diabetes drug …
Novo resubmits FDA application for two diabetes drugs
March 27, 2015Sales and Marketing Danish, FDA, Novo Nordisk, Ryzodeg, Tresiba, diabetes
Novo Nordisk will re-submit an FDA application for its diabetes drugs Tresiba and Ryzodeg two years after their initial rejection …
AstraZeneca and Harvard team up for diabetes research
March 25, 2015Research and Development, Sales and Marketing AZ, AstraZeneca, Havard, cardiovascular, diabetes, metabolic
AstraZeneca is to work with Harvard University’s department of stem cell and regenerative biology to develop new treatments in diabetes. …
Lilly and Boehringer diabetes drug sees US launch
March 24, 2015Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin
Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
Latest content
